PDCD1 and non-small cell lung carcinoma: RATIONALE 307 is one of the first phase 3 trials of a PD-1 inhibitor in combination with chemotherapy for sq-NSCLC.Tislelizumab+carboplatin+nab-paclitaxel/paclitaxel (T+CnP/T+CP) dramatically improved PFS and ORR and provided evidence of stable safety/tolerability compared to carboplatin+nab-paclitaxel/paclitaxel(CnP/CP).